002004.SHE Huapont Life Sciences Co Ltd
- Market cap
- CNY 9.21B
- P/E
- 16.0x
- P/B
- 0.86x
- ROE
- 6.3%
- Dividend yield
- 7.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002004.SHE undervalued?
Graham number002004.SHE trades 21.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Huapont Life Sciences Co Ltd fundamental analysis
No fundamental analysis for Huapont Life Sciences Co Ltd yet.
Huapont Life Sciences Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. It is involved in the production and sale of pharmaceutical preparations and raw materials. The company also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management products. In addition, it provides pesticide technical, intermediate and prepar…
Full company profileHuapont Life Sciences Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Huapont Life Sciences Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.09B | 9.18B | 10.6B | 10.1B | 10.9B | 12.4B | 13.2B | 11.6B | 11.7B | 11.5B | 11.6B |
| Gross Profit | 2.29B | 2.89B | 4.23B | 4.64B | 4.41B | 4.67B | 5.26B | 4.39B | 3.84B | 4.25B | 4.49B |
| Operating Income | 651M | 706M | 1.09B | 1.16B | 1.19B | 1.33B | 1.64B | 927M | -127M | 1.51B | 1.78B |
| EBITDA | 1.43B | 1.66B | 2.30B | 2.35B | 2.46B | 2.49B | 2.84B | 2.09B | 1.14B | 2.43B | 1.60B |
| Net Income | 567M | 506M | 506M | 620M | 652M | 668M | 433M | 302M | -299M | 713M | 628M |
| EPS | 0.28 | 0.25 | 0.25 | 0.31 | 0.33 | 0.34 | 0.22 | 0.15 | -0.15 | 0.36 | 0.32 |
| Balance Sheet | |||||||||||
| Total Assets | 24.2B | 29.1B | 26.6B | 26.6B | 28.2B | 30.0B | 30.0B | 30.7B | 29.5B | 29.0B | 28.7B |
| Total Liabilities | 13.5B | 15.8B | 13.8B | 13.4B | 14.1B | 14.2B | 13.5B | 14.1B | 14.0B | 12.0B | 11.7B |
| Shareholders' Equity | 9.65B | 9.49B | 9.06B | 9.34B | 9.63B | 10.1B | 10.2B | 10.1B | 9.34B | 10.2B | 10.0B |
| Cash & Short-term Investments | 6.03B | 7.71B | 4.35B | 4.05B | 4.98B | 5.42B | 4.89B | 5.61B | 3.94B | 2.86B | 2.85B |
| Total Debt | 8.98B | 11.5B | 9.72B | 8.92B | 9.13B | 8.57B | 8.05B | 8.63B | 6.56B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 512M | 591M | 1.91B | 2.08B | 2.37B | 1.27B | 2.41B | 1.59B | 1.63B | 2.10B | - |
| Capital Expenditure | 651M | 973M | 1.10B | 1.43B | 1.23B | 1.26B | 1.13B | 1.28B | 956M | 638M | 539M |
| Free Cash Flow | -139M | -381M | 809M | 649M | 1.14B | 13.2M | 1.28B | 305M | 669M | 1.46B | 1.51B |
| Ratios | |||||||||||
| ROE | 5.9% | 5.3% | 5.6% | 6.6% | 6.8% | 6.6% | 4.3% | 3.0% | -3.2% | 7.0% | 6.3% |
| ROA | 2.3% | 1.7% | 1.9% | 2.3% | 2.3% | 2.2% | 1.4% | 1.0% | -1.0% | 2.5% | 2.2% |
| Net Profit Margin | 8.0% | 5.5% | 4.8% | 6.1% | 6.0% | 5.4% | 3.3% | 2.6% | -2.6% | 6.2% | 5.4% |
| Debt to Equity | 0.93x | 1.21x | 1.07x | 0.96x | 0.95x | 0.85x | 0.79x | 0.85x | 0.70x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Huapont Life Sciences Co Ltd dividends
- Dividend yield
- 7.26%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 93.7%
- Ex-dividend date
- Sep 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 668M | 0.34 | 93.7% |
| 2024 | CNY 754M | 0.38 | - |
| 2023 | CNY 756M | 0.38 | 250.3% |
| 2022 | CNY 436M | 0.22 | 100.5% |
| 2021 | CNY 436M | 0.22 | 65.2% |
| 2020 | CNY 436M | 0.22 | 66.8% |
| 2019 | CNY 436M | 0.22 | 70.2% |
| 2018 | CNY 988M | 0.49 | 195.1% |
| 2017 | CNY 761M | 0.38 | 150.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 25:10 on May 27, 2015.
Who owns Huapont Life Sciences Co Ltd
- Insiders 34.49%
- Institutions 4.17%
- Public & others 61.34%
- Shares outstanding 1.98B
- Free float 1.29B
Huapont Life Sciences Co Ltd company profile
- Company name
- Huapont Life Sciences Co Ltd
- Ticker
- 002004.SHE
- ISIN
- CNE000001JJ6
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 7, 2004
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 11,950
- Fiscal year end
- December
- Address
- 69 Renhe Xingguang Avenue, Chongqing, China, 401121
- Phone
- 86 23 6788 6900
- Website
- huapont.com.cn
About Huapont Life Sciences Co Ltd
Huapont Life Sciences Co.,Ltd. engages in the medicine, medical care, agrochemicals, new materials, tourism, and other businesses in China and internationally. It is involved in the production and sale of pharmaceutical preparations and raw materials. The company also offers medicines for skin, tuberculosis, anti-infection, respiratory, anti-tumor, and cardiovascular, as well as health management products. In addition, it provides pesticide technical, intermediate and preparation products, and GLP registration technical services. Further, the company engages in the research and development, production, and sales of fine chemical products and polymer materials, as well as provides tourism services and agent for the promotion of preparation products. The company was formerly known as Huapont-Nutrichem Co., Ltd. and changed its name to Huapont Life Sciences Co.,Ltd. in September 2015. Huapont Life Sciences Co.,Ltd. was founded in 1992 and is headquartered in Chongqing, China.
Huapont Life Sciences Co Ltd management
3- Mr. Hai An ZhangGM & Director · born 1981
- Mr. Jian WangCFO & Accounting Supervisor · born 1976
- Ms. Jingjing HuBoard Secretary · born 1984